It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
When time is of the essence, knowing ways to get emergency cash quickly can make a difference. Explore your options.
23,900 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
A 55-year-old walks away with $1.2 million in his 401(K) only to risk losing access to the money before 59½ after a r...
Global markets slide as tech shares drop on fading AI chip optimism. Analysts warn the downturn could spill into broa...
Strategy continues to deploy capital into Bitcoin as market dynamics evolve, highlighting the tension between bold cr...
Lynx Investment Advisory recently disclosed a meaningful stake in the Akre Focus ETF, signaling confidence in a quali...
C3.AI reports two consecutive quarterly revenue declines, forcing investors to reassess its enterprise AI strategy as...
Nvidia topped quarterly estimates with a sizable revenue beat and raised guidance, yet its stock slipped as traders w...
A multi-jurisdictional probe led to indictments for 62 people connected to a massive crypto-laundering operation. The...
Redwood Trust closed a $391 million securitization backed by non-qualified mortgages, the inaugural deal under its ex...
Carnival reports a sharp rise in adjusted earnings for 2025 and improves leverage metrics, even as fuel costs and sec...
A hidden tax trap could sneak up on retirees: required minimum distributions from IRAs and 401(k)s can push Social Se...
When you hear an insider just sold 10,000 shares, it triggers questions. This guide explains how to interpret such mo...